Weight Loss

Rhythm Pharmaceuticals announced positive results from two phase 3 clinical trials evaluating setmelanotide, a melanocortin-4 receptor agonist for the treatment of rare congenital forms of obesity, according to a company press release.

A home-based exercise and/or weight loss intervention failed to improve breast cancer-related lymphedema outcomes among breast cancer survivors with overweight, according to results from the WISER Survivor randomized trial published in JAMA Oncology.

People with diabetes have elevated risks for CVD and events, and these risks are compounded by hypertension, a common comorbidity.

Individuals engaging in activities such as watching television or playing video games tend to eat more and consume greater amounts of protein, carbohydrates, fat and saturated fat than when not taking part in such activities, according to findings published in Obesity.

Adults with diabetes who took part in monthly lifestyle counseling appeared to reduce their risks for cardiovascular events and all-cause mortality compared with those who did not undergo regular counseling, according to findings published in Diabetes Care.

Alternate-day fasting lowered levels of fasting insulin and insulin resistance to a greater degree than calorie restriction among adults with overweight or obesity and insulin resistance, according to findings published in Obesity.

The FDA has approved extended-release phentermine plus topiramate as an addition to a reduced-calorie diet and exercise for chronic weight management in overweight or obese adults. The agency’s decision represents only the second approval of a weight-loss drug in more than a decade.

Obesity is a rapidly increasing problem in the United States and worldwide, with more than 30% of adult Americans now affected. Unfortunately, we are lacking in effective therapies to promote significant weight loss.